Dyne Therapeutics Announces Pricing of $168 Million Public Offering
January 20 2021 - 8:05PM
Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company
focused on advancing innovative life-transforming therapeutics for
people living with genetically driven diseases, today announced the
pricing of an underwritten public offering of 6,000,000 shares of
its common stock at a public offering price of $28.00 per share. In
addition, Dyne has granted the underwriters a 30-day option to
purchase up to 900,000 additional shares of common stock at the
public offering price, less the underwriting discount and
commissions. All of the shares are being offered by Dyne.
The gross proceeds of the offering, before deducting the
underwriting discount and commissions and other offering expenses
payable by Dyne, are expected to be approximately $168 million,
excluding any exercise of the underwriters’ option to purchase
additional shares. The offering is expected to close on Monday,
January 25, 2021, subject to customary closing conditions.
J.P. Morgan, Jefferies, Piper Sandler and Stifel are acting as
joint book-running managers for the offering.
A registration statement relating to the securities being sold
in this offering has been filed with, and declared effective by,
the Securities and Exchange Commission. This offering is being
made only by means of a prospectus. Copies of the final prospectus
relating to this offering may be obtained, when available, from
J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions,
1155 Long Island Avenue, Edgewood, New York 11717, via telephone at
(866) 803-9204 or via email at prospectus-eq_fi@jpmchase.com;
Jefferies LLC, Attention: Equity Syndicate Prospectus Department,
520 Madison Avenue, 2nd Floor, New York, New York 10022, via
telephone at (877) 821-7388 or via email at
Prospectus_Department@Jefferies.com; Piper Sandler & Co.,
Attention: Prospectus Department, 800 Nicollet Mall, J12S03,
Minneapolis, Minnesota 55402, via telephone at (800) 747-3924 or
via email at prospectus@psc.com; or Stifel, Nicolaus & Company,
Incorporated, Attention: Syndicate, One Montgomery Street, Suite
3700, San Francisco, California 94104, via telephone at (415)
364-2720 or via email at syndprospectus@stifel.com.
This press release shall not constitute an offer to sell, or a
solicitation of an offer to buy, these securities, nor shall there
be any offer or sale of these securities in any state or
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to the registration or qualification under the
securities laws of any such state or jurisdiction.
About Dyne Therapeutics
Dyne Therapeutics is building a leading muscle disease company
focused on advancing innovative life-transforming therapeutics for
people living with genetically driven diseases. The Company is
utilizing its proprietary FORCE™ platform to overcome the current
limitations of muscle tissue delivery with modern oligonucleotide
therapeutic candidates. Dyne is developing a broad portfolio of
therapeutics for muscle diseases, including programs in myotonic
dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and
facioscapulohumeral muscular dystrophy (FSHD).
Contact:
Dyne TherapeuticsAmy Reillyareilly@dyne-tx.com 857-341-1203
Dyne Therapeutics (NASDAQ:DYN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Dyne Therapeutics (NASDAQ:DYN)
Historical Stock Chart
From Jul 2023 to Jul 2024